[Federal Register Volume 61, Number 71 (Thursday, April 11, 1996)]
[Notices]
[Pages 16103-16104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-9001]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of a Partial Exclusive License: Recombinant 
Heregulin PE-40 Toxin Cancer Therapeutics Which Bind to the Ligand 
Binding Site of the erbB3 and/or erbB4 Proteins

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. 203(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a partial exclusive license in the United States to practice the 
invention embodied in U.S. Patent Application Number 06/911,227 (issued

[[Page 16104]]

on January 9, 1990 as U.S. Patent No. 4,892,827) entitled ``Recombinant 
Pseudomonas Exotoxins: Construction of an Active Immunotoxin with Low 
Side Effects'', to The Cooperative Research Centre for 
Biopharmaceutical Research Pty., Ltd., having a place of business in 
Darlinghurst Australia. The patent rights in these inventions have been 
assigned to the United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless, within 60 days 
from the date of this published Notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The field of use would be limited to recombinant heregulin PE-40 
toxin cancer therapeutics which bind to the ligand binding site of the 
erbB3 and/or erbB4 proteins.
    The present invention relates to modifications of recombinant 
Pseudomonas exotoxin with insertion of various targeting molecules 
specific for a given target site. The modified exotoxin of this 
invention may prove to be a valuable cancer therapeutic when fused to 
various target-specific cell recognition proteins. The modifications 
result in reduced non-specific cytotoxicity while increasing target 
specific cytotoxicity.

ADDRESSES: Requests for a copy of the subject issued patent, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Mr. Larry M. Tiffany, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852. Telephone: (301) 496-7056; Facsimile: 
(301) 402-0220. Only written comments and/or applications for a license 
which are received by the NIH Office of Technology Transfer on or 
before June 10, 1996, will be considered. Comments and objections will 
not be made available for public inspection and, to the extent 
permitted by law, will not be subject to disclosure under the Freedom 
of Information Act, 5 U.S.C. 552.

    Dated: March 29, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-9001 Filed 4-10-96; 8:45 am]
BILLING CODE 4140-01-M